Understanding patient perspectives in the management of their muscle-invasive bladder cancer

被引:0
|
作者
Chowdhury, Deepro [1 ]
Apolo, Andrea B. [2 ]
Jiang, Di Maria [1 ]
Skinner, Eila C. [4 ]
Chisolm, Stephanie [3 ]
Bangs, Rick [3 ]
Maganti, Manjula [1 ]
Steinberg, Gary D. [5 ]
Kaag, Matthew [6 ]
Efstathiou, Jason A. [7 ]
Sridhar, Srikala S. [1 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] NCI, Bethesda, MD USA
[3] Bladder Canc Advocacy Network, Bethesda, MD USA
[4] Stanford Canc Ctr GU Surg Oncol, Stanford, CA USA
[5] Rush Univ, Med Coll, Chicago, IL USA
[6] Penn State Milton S Hershey Med Ctr, Hershey, PA USA
[7] Massachusetts Gen Hosp, Boston, MA USA
关键词
muscle-invasive bladder cancer; patient survey; patient education; bladder-sparing; patient-reported outcomes; multidisciplinary management; PATTERNS;
D O I
10.1111/bju.16695
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with muscle-invasive bladder cancer (MIBC). Materials and Methods We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website between August 2013 and September 2014 (Cohort A) and again between June 2023 and April 2024 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment, proportion seeing a medical oncologist or radiation oncologist, treatments offered/received, and patient satisfaction with their treatment choices. Results Overall, 337 self-selected patients mostly white males from the US or Canada, with at least an undergraduate education completed the survey. There were 243 patients in Cohort A and 94 patients in Cohort B. The median age (range) at diagnosis was 61 (31-93) in Cohort A and 63 (38-87) in Cohort B. The most common presenting symptom was hematuria. In Cohorts A and B, 35% vs 30% (P = 0.56) waited >3 months to seek medical attention, and in 38% vs 43% (P = 0.76) it took >3 months to obtain a diagnosis. Men were more likely than women to be diagnosed within 1-2 months in both cohorts (Cohort A: 68% vs 47%; P = 0.03, Cohort B: 70% vs 37%; P = 0.03). Preoperative consultation with a radiation oncologist and bladder-sparing use were infrequent. More patients in Cohort A (77%) felt they had enough time to make decisions compared to Cohort B (67%) (P = 0.004). Most patients were satisfied with their treatment choices. Conclusions There are ongoing areas of unmet need in MIBC, including reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer
    Timur Mitin
    Ananya Choudhury
    World Journal of Urology, 2019, 37 : 1767 - 1772
  • [22] Bladder preservation in muscle-invasive bladder cancer
    Stackl, W
    Baierlein, M
    Albrecht, W
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (03): : 357 - 360
  • [23] Bladder conservation for muscle-invasive bladder cancer
    Hoskin, Peter
    Dubash, Suraiya
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (08) : 1015 - 1020
  • [24] NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer
    Flaig, Thomas W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05): : 591 - 593
  • [25] Aggressive management of elderly patients with muscle-invasive bladder cancer
    Weizer, Alon Z.
    Montie, James E.
    Lee, Cheryl T.
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (07): : 346 - 347
  • [26] Aggressive management of elderly patients with muscle-invasive bladder cancer
    Alon Z Weizer
    James E Montie
    Cheryl T Lee
    Nature Clinical Practice Urology, 2006, 3 : 346 - 347
  • [27] Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer
    Chedgy, Edmund Charles Paul
    Black, Peter C.
    JAMA ONCOLOGY, 2016, 2 (07) : 855 - 856
  • [28] Radical transurethral resection in the management of muscle-invasive bladder cancer
    Grob, BM
    Macchia, RJ
    JOURNAL OF ENDOUROLOGY, 2001, 15 (04) : 419 - 423
  • [29] The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
    Juffs, HG
    Moore, MJ
    Tannock, IF
    LANCET ONCOLOGY, 2002, 3 (12): : 738 - 747
  • [30] Chemotherapy for Muscle-Invasive Bladder Cancer
    Patrizia Trenta
    Fabio Calabrò
    Linda Cerbone
    Cora N. Sternberg
    Current Treatment Options in Oncology, 2016, 17